Live Breaking News & Updates on Updated Label Adds Primary Hyperlipidemia

Stay updated with breaking news from Updated label adds primary hyperlipidemia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

U.S. FDA Updates LDL-C Lowering Indication for Esperion's NEXLETOL® (bempedoic acid) Tablet and ... | Region

– Updated Label Adds Primary Hyperlipidemia, Removes Maximally Tolerated Statin Requirement, Removes Limitation of Use – ....

Sheldon Koenig , Tiffany Aldrich , Alexis Callahan , Esperion Therapeutics Inc , Exchange Commission , Drug Administration , Updated Label Adds Primary Hyperlipidemia , Removes Maximally Tolerated Statin Requirement , Removes Limitation , Risk Reduction Labels Remain , Anticipated Approval , Supplemental New Drug Applications , Cholesterol Lowering , Inhibiting Regimen , Esperion Therapeutics , Adverse Event , Contact Information ,